Take a deeper dive

Nuventra’s Webinar Library

Were you unable to attend our live webinars? Watch Nuventra’s past webinars and hear directly from some of our Senior Consultants who are experts on these Clinical Pharmacology topics.  Fill out the forms below for more details and to access our past webinars recordings.

Available Webinars:


PK 101 Part 1: Introducing Pharmacokinetic Concepts & Noncompartmental Analysis

PK data contributes to much of what is on a drug package label. NCA analysis provides the most elementary information for a drug (i.e., the rate and extent of absorption and elimination). Hear Mark Bush, PhD present Part one of this PK 101 series covering  PK and NCA fundamentals in the webinar titled, “PK 101 Part 1: Introducing Pharmacokinetic Concepts & Noncompartmental Analysis.

Pk 101 Part 1 Webinar

Timing Considerations for Clinical Pharmacology Studies in Oncology Drug Development

Clinical pharmacology plans are not “one size fits all.” This is especially true for oncology, as the time from the first-in-human dose to approval is shorter for oncology relative to other indications and the medical need is substantial. Hear from Nuventra’s consultants, Gene Williams and Brian Furmanski as they present this webinar titled, “Timing Considerations for Clinical Pharmacology Studies in Oncology Drug Development.

Oncology Webinar

Designing Smarter Clinical Trials with Modeling & Simulation Approaches

With modeling and simulation, your existing data can be leveraged to provide important insights, design more efficient trials, and used to potentially avoid certain clinical studies, saving money and time. This webinar will cover modeling and simulation fundamentals, real-world examples, and best practices to implement in your development program. Hear from Mark Sale, M.D., and Lauren Lohmer, Ph.D. as they present the webinar titled, “Designing Smarter Clinical Trials with Modeling & Simulation Approaches.”

Modeling & Simulation Webinar

The Path to IND – Roadblocks, Milestones, and Regulatory Strategy

The Investigational New Drug (IND) application is the primary pathway through which new drugs and biologics are approved to be tested in humans. But, what exactly is an IND and does your program really need one? What are the requirements for a successful IND and what paths can you take to get there? Hear from Todd Shearer, Ph.D. and Brian Furmanski, Ph.D., as they present this webinar titled, “The Path to IND – Roadblocks, Milestones, and Regulatory Strategy.

The Path to IND Webinar

Addressing the Challenges of Drug Discovery and Delivery for Combination Peptide Therapeutics

There has been growing interest and activity in the use of peptide therapeutics to treat a variety of human diseases. This webinar will present approaches to discover, optimize, assess, and deliver combination peptide therapeutics for treatment of metabolic diseases. Hear from Nuventra’s Mark Bush PhD, and Intarcia Therapeutics’ Paul L. Feldman PhD, as they present this webinar titled, “Addressing the Challenges of Drug Discovery and Delivery for Combination Peptide Therapeutics.

Peptide Webinar

Explore Our Blog

IVIVC Flask

What is IVIVC?

An in vitro in vivo correlation (IVIVC) is a predictive mathematical model that describes the relationship between an in vitro…

Read More

FDA Recently Revised the 1999 Population Pharmacokinetic Guidance

The US Food and Drug Administration (FDA) released a new draft guidance on Population Pharmacokinetics (popPK) in July of 2019.…

Read More

Data Standards: Considerations for Regulatory Submissions

Drug applications go through comprehensive reviews of both nonclinical and clinical study data. Historically, these datasets were structured according to…

Read More